Transmitted HIV resistance to first-line antiretroviral therapy in Lima, Peru.

Antiviral resistance and correlates of virologic failure in the first cohort of HIV-infected children gaining access to structured antiretroviral therapy in Lima, Peru: a cross-sectional analysis. BMC Infect Dis (2013) 0.91

[Risk factors associated with virologic failure in HIV- infected patients receiving antiretroviral therapy at a public hospital in Peru]. Rev Chilena Infectol (2013) 0.85

The emergence of drug resistant HIV variants and novel anti-retroviral therapy. Asian Pac J Trop Biomed (2013) 0.81

Surveillance of HIV Transmitted Drug Resistance in Latin America and the Caribbean: A Systematic Review and Meta-Analysis. PLoS One (2016) 0.79

Development and validation of an oligonucleotide ligation assay to detect lamivudine resistance in hepatitis B virus. J Virol Methods (2016) 0.75

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med (1998) 53.26

Rapid and simple method for purification of nucleic acids. J Clin Microbiol (1990) 44.73

Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med (2002) 9.70

Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One (2009) 8.37

Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis (2006) 5.90

Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis (2008) 5.20

Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes. J Infect Dis (2009) 4.48

Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacy. PLoS Med (2008) 4.12

HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS (2007) 3.94

Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis (2011) 3.59

Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis (2005) 3.52

Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. JAMA (2011) 3.08

Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection. J Virol (2008) 3.04

Progressive reversion of human immunodeficiency virus type 1 resistance mutations in vivo after transmission of a multiply drug-resistant virus. Clin Infect Dis (2003) 2.92

HIV-1 drug resistance mutations: an updated framework for the second decade of HAART. AIDS Rev (2008) 2.88

Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.-2006. AIDS (2010) 2.62

Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients. Clin Infect Dis (2009) 2.36

Underestimation of HIV type 1 drug resistance mutations: results from the ENVA-2 genotyping proficiency program. AIDS Res Hum Retroviruses (2002) 2.20

Comparison of oligonucleotide ligation assay and consensus sequencing for detection of drug-resistant mutants of human immunodeficiency virus type 1 in peripheral blood mononuclear cells and plasma. J Clin Microbiol (2004) 1.97

Oligonucleotide ligation assay for detecting mutations in the human immunodeficiency virus type 1 pol gene that are associated with resistance to zidovudine, didanosine, and lamivudine. J Clin Microbiol (1998) 1.92

Prevalence, incidence, and residual risk of human immunodeficiency virus among community and replacement first-time blood donors in São Paulo, Brazil. Transfusion (2005) 1.84

Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies. AIDS (2010) 1.83

Rapid and sensitive oligonucleotide ligation assay for detection of mutations in human immunodeficiency virus type 1 associated with high-level resistance to protease inhibitors. J Clin Microbiol (2002) 1.66

Clade B HIV-1 superinfection with wild-type virus after primary infection with drug-resistant clade B virus. AIDS (2003) 1.52

Transmission of HIV-1 drug-resistant variants: prevalence and effect on treatment outcome. Clin Infect Dis (2010) 1.52

Optimization of the oligonucleotide ligation assay, a rapid and inexpensive test for detection of HIV-1 drug resistance mutations, for non-North American variants. J Acquir Immune Defic Syndr (2008) 1.43

HIV-1 pol mutation frequency by subtype and treatment experience: extension of the HIVseq program to seven non-B subtypes. AIDS (2006) 1.40

Brazilian Network for HIV Drug Resistance Surveillance: a survey of individuals recently diagnosed with HIV. J Int AIDS Soc (2009) 1.37

The national response to the HIV/AIDS epidemic in Peru: accomplishments and gaps--a review. J Acquir Immune Defic Syndr (2009) 1.30

Detection and quantification of multiple drug resistance mutations in HIV-1 reverse transcriptase by an oligonucleotide ligation assay. J Hum Virol (2002) 1.25

Primary drug resistance and transmission analysis of HIV-1 in acute and recent drug-naïve seroconverters in Singapore. HIV Med (2009) 1.21

Linking HIV and antiretroviral drug resistance surveillance in Peru: a model for a third-generation HIV sentinel surveillance. J Acquir Immune Defic Syndr (2006) 1.18

Prevalence and predictors of antiretroviral drug resistance in newly diagnosed HIV-1 infection. J Antimicrob Chemother (2007) 1.16

Understanding transmitted HIV resistance through the experience in the USA. Int J Infect Dis (2009) 1.14

Monotypic human immunodeficiency virus type 1 genotypes across the uterine cervix and in blood suggest proliferation of cells with provirus. J Virol (2009) 1.11

Sensitive oligonucleotide ligation assay for low-level detection of nevirapine resistance mutations in human immunodeficiency virus type 1 quasispecies. J Clin Microbiol (2007) 1.08

Detection of HIV-1 drug resistance in women following administration of a single dose of nevirapine: comparison of plasma RNA to cellular DNA by consensus sequencing and by oligonucleotide ligation assay. J Clin Microbiol (2010) 1.03

Drug-resistance mutations in antiretroviral-naïve patients with established HIV-1 infection in Mexico. HIV Med (2005) 1.00

High level of primary drug resistance in Mali. HIV Med (2010) 0.92

Increased detection of HIV-1 drug resistance at time of diagnosis by testing viral DNA with a sensitive assay. J Acquir Immune Defic Syndr (2009) 0.92

The use of resistance testing in the management of HIV-1-infected patients. Curr Opin HIV AIDS (2009) 0.90

Development and evaluation of an oligonucleotide ligation assay for detection of drug resistance-associated mutations in the human immunodeficiency virus type 2 pol gene. J Clin Microbiol (2007) 0.89

Prediction of the virological response to etravirine in clinical practice: Comparison of three genotype algorithms. J Med Virol (2009) 0.89

Prevalence of antiretroviral drug resistance among treatment-naive and treated HIV-infected patients in Venezuela. Mem Inst Oswaldo Cruz (2009) 0.88

Low-frequency HIV-1 drug resistance mutations can be clinically significant but must be interpreted with caution. J Antimicrob Chemother (2010) 0.87

Hidden drug resistant HIV to emerge in the era of universal treatment access in Southeast Asia. PLoS One (2010) 0.87

Antiretroviral drug resistance and phylogenetic diversity of HIV-1 in Chile. J Med Virol (2007) 0.87

Oligonucleotide ligation assay for detection of mutations associated with reverse transcriptase and protease inhibitor resistance in non-B subtypes and recombinant forms of human immunodeficiency virus type 1. J Clin Microbiol (2005) 0.86

Primary drug resistance in antiretroviral-naïve injection drug users. Int J Infect Dis (2008) 0.85

When do minority drug-resistant HIV-1 variants have a major clinical impact? J Infect Dis (2010) 0.82

Trends in drug resistance mutations in antiretroviral-naïve intravenous drug users of Rio de Janeiro. J Med Virol (2006) 0.81

Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med (2012) 27.84

Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis (2010) 5.35

Natural ventilation for the prevention of airborne contagion. PLoS Med (2007) 3.73

Microscopic observation drug susceptibility assay, a rapid, reliable diagnostic test for multidrug-resistant tuberculosis suitable for use in resource-poor settings. J Clin Microbiol (2004) 3.27

The detection of airborne transmission of tuberculosis from HIV-infected patients, using an in vivo air sampling model. Clin Infect Dis (2007) 2.28

Is pathology examination useful after early surgical abortion? Obstet Gynecol (2002) 2.12

The infectiousness of tuberculosis patients coinfected with HIV. PLoS Med (2008) 2.08

Tuberculosis mortality, drug resistance, and infectiousness in patients with and without HIV infection in Peru. Am J Trop Med Hyg (2006) 2.05

Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV. AIDS (2010) 2.04

Pharmacokinetics and safety of stavudine in HIV-infected pregnant women and their infants: Pediatric AIDS Clinical Trials Group protocol 332. J Infect Dis (2004) 1.67

Detection of nonnucleoside reverse-transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy. Clin Infect Dis (2008) 1.66

Upper-room ultraviolet light and negative air ionization to prevent tuberculosis transmission. PLoS Med (2009) 1.64

Infectious correlates of HIV-1 shedding in the female upper and lower genital tracts. AIDS (2007) 1.61

Microscopic observation drug susceptibility assay for tuberculosis screening before isoniazid preventive therapy in HIV-infected persons. Clin Infect Dis (2010) 1.60

Diagnosis of sputum-scarce HIV-associated pulmonary tuberculosis in Lima, Peru. Lancet (2005) 1.57

Differences in clinical manifestations among Cryptosporidium species and subtypes in HIV-infected persons. J Infect Dis (2007) 1.53

Planned multiple exposures to autologous virus in HIV type 1-infected pediatric populations increases HIV-specific immunity and reduces HIV viremia. AIDS Res Hum Retroviruses (2008) 1.52

Nevirapine resistance by timing of HIV type 1 infection in infants treated with single-dose nevirapine. Clin Infect Dis (2010) 1.47

A proof-of-concept study of short-cycle intermittent antiretroviral therapy with a once-daily regimen of didanosine, lamivudine, and efavirenz for the treatment of chronic HIV infection. J Infect Dis (2004) 1.37

Cryptosporidium species and genotypes in HIV-positive patients in Lima, Peru. J Eukaryot Microbiol (2003) 1.34

The epidemiology of intestinal microsporidiosis in patients with HIV/AIDS in Lima, Peru. J Infect Dis (2005) 1.33

Multidrug-resistant Mycobacterium tuberculosis in HIV-infected persons, Peru. Emerg Infect Dis (2003) 1.29

A molecular biologic study of Enterocytozoon bieneusi in HIV-infected patients in Lima, Peru. J Eukaryot Microbiol (2003) 1.27

Cervicovaginal shedding of HIV type 1 is related to genital tract inflammation independent of changes in vaginal microbiota. AIDS Res Hum Retroviruses (2010) 1.26

Recombinant interferon- gamma 1b as adjunctive therapy for AIDS-related acute cryptococcal meningitis. J Infect Dis (2004) 1.26

Comparisons of anemia, thrombocytopenia, and neutropenia at initiation of HIV antiretroviral therapy in Africa, Asia, and the Americas. Int J Infect Dis (2010) 1.20

Mixed Cryptosporidium infections and HIV. Emerg Infect Dis (2006) 1.14

Suspected premature menopause. BMJ (2008) 1.14

Interaction between lactobacilli, bacterial vaginosis-associated bacteria, and HIV Type 1 RNA and DNA Genital shedding in U.S. and Kenyan women. AIDS Res Hum Retroviruses (2012) 1.11

Predicting biopsychosocial outcomes for heroin users in primary care treatment: a prospective longitudinal cohort study. Br J Gen Pract (2013) 1.11

Compartmentalization of HIV-1 within the female genital tract is due to monotypic and low-diversity variants not distinct viral populations. PLoS One (2009) 1.11

Optimization and evaluation of a PCR assay for detecting toxoplasmic encephalitis in patients with AIDS. J Clin Microbiol (2002) 1.10

Effects of CCR5-delta32 and CCR2-64I alleles on disease progression of perinatally HIV-1-infected children: an international meta-analysis. AIDS (2003) 1.07

Postmortem findings and opportunistic infections in HIV-positive patients from a public hospital in Peru. Pathol Res Pract (2006) 1.06

Immune reconstitution after receipt of highly active antiretroviral therapy in children with advanced or progressive HIV disease and complete or partial viral load response. J Infect Dis (2005) 1.02

Diminished human immunodeficiency virus type 1 DNA yield from dried blood spots after storage in a humid incubator at 37 degrees C compared to -20 degrees C. J Clin Microbiol (2008) 1.02

Prevalence of human papillomavirus genotypes in HIV-1-infected women in Seattle, USA and Nairobi, Kenya: results from the Women's HIV Interdisciplinary Network (WHIN). Int J Infect Dis (2010) 0.98

A multinational study of neurological performance in antiretroviral therapy-naïve HIV-1-infected persons in diverse resource-constrained settings. J Neurovirol (2011) 0.96

Laser cutting eliminates nucleic acid cross-contamination in dried-blood-spot processing. J Clin Microbiol (2012) 0.94

HIV drug resistance in mothers and infants following use of antiretrovirals to prevent mother-to-child transmission. Curr HIV Res (2013) 0.94

Model for assessment of proficiency of human immunodeficiency virus type 1 sequencing-based genotypic antiretroviral assays. J Clin Microbiol (2005) 0.93

Effect of cessation of zidovudine prophylaxis to reduce vertical transmission on maternal HIV disease progression and survival. J Acquir Immune Defic Syndr (2003) 0.93

A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine. Clin Infect Dis (2011) 0.93

Oligonucleotide ligation assay detects HIV drug resistance associated with virologic failure among antiretroviral-naive adults in Kenya. J Acquir Immune Defic Syndr (2014) 0.91

Cross-contamination during processing of dried blood spots used for rapid diagnosis of HIV-1 infection of infants is rare and avoidable. J Virol Methods (2009) 0.89

Evaluation of a PCR-based universal heteroduplex generator assay as a tool for rapid detection of multidrug-resistant Mycobacterium tuberculosis in Peru. J Clin Microbiol (2003) 0.88

Effects of short-course zidovudine on the selection of nevirapine-resistant HIV-1 in women taking single-dose nevirapine. J Infect Dis (2012) 0.85

Effect of acyclovir on HIV-1 set point among herpes simplex virus type 2-seropositive persons during early HIV-1 infection. J Infect Dis (2010) 0.83

Associations between genital tract infections, genital tract inflammation, and cervical cytobrush HIV-1 DNA in US versus Kenyan women. J Acquir Immune Defic Syndr (2013) 0.83

Purification of Enterocytozoon bieneusi spores from stool specimens by gradient and cell sorting techniques. J Clin Microbiol (2004) 0.83

Low concentrations of HIV-1 DNA at birth delays diagnosis, complicating identification of infants for antiretroviral therapy to potentially prevent the establishment of viral reservoirs. Clin Infect Dis (2014) 0.81

Survey of patients' view on functional split of consultant psychiatrists. BMC Health Serv Res (2013) 0.81

Effects of pregnancy and bacterial vaginosis on proinflammatory cytokine and secretory leukocyte protease inhibitor concentrations in vaginal secretions. J Pregnancy (2010) 0.81

Healthy Neonates Possess a CD56-Negative NK Cell Population with Reduced Anti-Viral Activity. PLoS One (2013) 0.81

HIV vaccine-induced sero-reactivity: a challenge for trial participants, researchers, and physicians. Vaccine (2015) 0.80

Closing the osteoporosis management gap in primary care: a secondary prevention of fracture programme. Curr Med Res Opin (2005) 0.79

Are the gates to be thrown open? Br J Gen Pract (2010) 0.78

Monitoring of HIV type 1 DNA load and drug resistance in peripheral blood mononuclear cells during suppressive antiretroviral therapy does not predict virologic failure. AIDS Res Hum Retroviruses (2012) 0.78

Structured treatment interruptions (STIs) in HIV-1 infected pediatric populations increases interferon gamma production and reduces viremia. Vaccine (2008) 0.78

Detection of hydrogen peroxide-producing Lactobacillus species in the vagina: a comparison of culture and quantitative PCR among HIV-1 seropositive women. BMC Infect Dis (2012) 0.77

[Probable vertical transmission of the influenza virus A (H1N1): apropos of a case]. Rev Peru Med Exp Salud Publica (2010) 0.77

Increasing HIV-1 pretreatment drug resistance among antiretroviral-naïve adults initiating treatment between 2006 and 2014 in Nairobi, Kenya. AIDS (2016) 0.77

Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons. AIDS (2016) 0.77

Hearing loss in adults. BMJ (2013) 0.76

"Riding the bumpy seas": or the impact of the Knowledge Skills Framework component of the Agenda for Change initiative on staff in intermediate care settings. J Interprof Care (2010) 0.76

Patient's ethnicity and use of therapies in rheumatoid arthritis. J Rheumatol (2007) 0.75

Leaders, leadership and future primary care clinical research. BMC Fam Pract (2008) 0.75

Biomarkers of inflammation in HIV-infected Peruvian men and women before and during suppressive antiretroviral therapy. AIDS (2015) 0.75

Migrant health. Br J Gen Pract (2016) 0.75

[Guillain Barré syndrome in association with Brucellosis]. Rev Peru Med Exp Salud Publica (2010) 0.75

[Don't forget nonalcoholic fatty liver disease in patients with HIV infection]. Rev Gastroenterol Peru (2009) 0.75

The development and evaluation of a community attachment scheme for first-year medical students. Med Teach (2003) 0.75

Multiple High-Risk HPV Types Contribute to Cervical Dysplasia in Ugandan Women Living with HIV on Antiretroviral Therapy. J Acquir Immune Defic Syndr (2022) 0.75

[Recurrent diarrhea due to Cystoisopora belli in HIV/AIDS patients receiving HAART]. Rev Peru Med Exp Salud Publica (2013) 0.75